Morgan Stanley Believes the Long-Term Thesis on Aetna is Intact

In a report published Friday, Morgan Stanley analyst Andrew Schenker reiterated an Overweight rating and $83.00 price target on

. In the report, Morgan Stanley noted, “AET maintained its adjusted EPS guidance of ‘at least $6.25' for FY14 after reporting $6.25 for FY13. We continue to view this outlook as very achievable given enrollment growth, capital deployment, and CVH synergies. As such, we have maintained our 2014 EPS of $6.72, which reflects 8% Y/Y growth.” Aetna closed on Thursday at $67.92.